🔍

SOLARA - Solara Active

📊 NSE: SOLARA 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 13:32

📢 Recent Corporate Announcements

Solara Receives US FDA EIR for Puducherry Facility with VAI Classification

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 28 Apr 2026, 05:01 PM

Solara Active Pharma Sciences has successfully closed a US FDA inspection at its Puducherry Ibuprofen manufacturing facility. The unannounced inspection, conducted between February 2 and February 6, 2026, initially resulted in four procedural Form 483 observations. Following the company's timely response, the US FDA issued an Establishment Inspection Report (EIR) on April 24, 2026, classifying the facility as Voluntary Action Indicated (VAI). This closure confirms continued cGMP compliance and secures the regulatory standing of a key site catering to international markets.

Successful closure of US FDA inspection at the Puducherry Ibuprofen manufacturing site
Received Establishment Inspection Report (EIR) with 'Voluntary Action Indicated' (VAI) status on April 24, 2026
Inspection conducted from Feb 2 to Feb 6, 2026, resulted in 4 procedural Form 483 observations
The Puducherry site is a core facility approved by multiple global agencies including US FDA, EDQM, and MHRA

💡 Investors should view this as a significant positive development that removes regulatory overhang on a key manufacturing asset. The successful EIR receipt validates the company's quality systems and ensures uninterrupted supply to the US market.

Solara Active Pharma Submits Quarterly SEBI Compliance Certificate for March 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Apr 2026, 04:53 PM

Solara Active Pharma Sciences Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, provided by Cameo Corporate Services Limited, confirms the processing of share dematerialization requests for the quarter ended March 31, 2026. This is a standard regulatory filing required for all listed companies in India to ensure shareholding records are updated with depositories. The filing indicates that the company is adhering to its administrative and regulatory obligations.

Compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Covers the reporting period for the quarter ended March 31, 2026.
Certificate issued by Registrar and Share Transfer Agent (RTA), Cameo Corporate Services Limited.
Confirms that share certificates received for dematerialization have been processed and records updated.

💡 No action is required as this is a routine administrative filing. Investors should continue to monitor the company's upcoming financial results for actual business performance.

Solara Pharma Announces Final Call of ₹112.50 per Rights Share; Record Date April 2, 2026

🟡 NEUTRAL ⭐ 7/10

FUNDRAISE 📅 24 Mar 2026, 10:37 AM

Solara Active Pharma Sciences has approved the second and final call for its partly paid-up rights shares. Shareholders holding these shares as of the record date, April 2, 2026, will be required to pay ₹112.50 per share. This payment consists of ₹3.00 towards face value and ₹109.50 towards securities premium. This procedural step completes the capital raising process initiated via the rights issue in May 2024.

Second and final call amount set at ₹112.50 per equity share.
Record date for identifying eligible partly-paid shareholders is April 02, 2026.
Call price breakdown: ₹3.00 face value and ₹109.50 securities premium per share.
Relates to the rights issue originally offered via the Letter of Offer dated May 09, 2024.

💡 Investors holding partly paid shares (SOLARAPP1) must pay the final call amount to convert them into fully paid shares. Failure to pay by the specified deadline will lead to the forfeiture of the shares and the initial investment.

Solara Active Pharma Sets April 2 Record Date for ₹112.50 Final Call on Rights Shares

🟡 NEUTRAL ⭐ 7/10

FUNDRAISE 📅 24 Mar 2026, 10:25 AM

Solara Active Pharma Sciences has scheduled the second and final call for its partly-paid rights shares issued in 2024. The company has fixed April 02, 2026, as the record date to identify shareholders liable for the payment. Investors must pay ₹112.50 per share, which consists of ₹3.00 towards face value and ₹109.50 towards securities premium. This final payment will convert the partly-paid shares into fully-paid equity shares of the company.

Final call amount fixed at ₹112.50 per equity share for partly-paid rights shares.
Record date for determining eligible shareholders is set for April 02, 2026.
Call price includes ₹3.00 face value and ₹109.50 securities premium per share.
The call is pursuant to the Rights Issue Letter of Offer dated May 09, 2024.
Successful payment will result in the conversion of partly-paid shares to fully-paid equity.

💡 Investors holding partly-paid shares (SOLARAPP1) should ensure they have sufficient liquidity to meet the ₹112.50 per share call to avoid the risk of share forfeiture. Failure to pay the final call will lead to the loss of the initial investment made during the rights issue.

Solara Active Pharma Announces Final Call of ₹112.50 per Rights Share; Record Date April 02

🟡 NEUTRAL ⭐ 7/10

FUNDRAISE 📅 24 Mar 2026, 10:19 AM

Solara Active Pharma Sciences has approved the second and final call for its partly paid-up rights shares. Shareholders holding these shares are required to pay ₹112.50 per share, which includes ₹3.00 for face value and ₹109.50 for securities premium. The company has established April 02, 2026, as the record date to determine eligible holders for the call notice. This final payment is the concluding step in the rights issue process initiated in May 2024 to convert partly paid shares into fully paid equity.

Final call amount set at ₹112.50 per rights share
Record date for determining eligible shareholders is April 02, 2026
Call amount comprises ₹3.00 face value and ₹109.50 securities premium
Process follows the Rights Issue Letter of Offer dated May 09, 2024

💡 Investors holding partly paid shares (SOLARAPP1) must pay the final call amount within the specified timeline to avoid forfeiture of their shares. Ensure funds are available before the payment window opens following the record date.

Solara Active Pharma Receives ₹161.92 Crore Income Tax Demand Notice

🔴 NEGATIVE ⭐ 7/10

LEGAL 📅 18 Mar 2026, 07:02 PM

Solara Active Pharma Sciences has received a significant tax demand notice of ₹161.92 Crores from the Income Tax Department for the Assessment Year 2019-20. The demand stems from the disallowance of certain expenses claimed by the company in its tax filings. The company has stated its intention to file an appeal against this order before the relevant Appellate Authority. Management believes the case has merit and does not currently expect a material financial impact, though the amount is substantial.

Received a Tax Demand Notice of ₹161.92 Crores under Section 156 of the Income Tax Act, 1961.
The demand pertains to Assessment Year 2019-20 following an audit of claimed expenses.
The order was passed by the Deputy Commissioner of Income Tax, Central Circle-3, Thane.
Company plans to contest the demand by filing an appeal with the Appellate Authority.
Management maintains that there will be no material financial impact due to the merits of their case.

💡 Investors should monitor the legal proceedings as the demand amount is significant relative to the company's financials. While the company is contesting, any unfavorable final ruling could impact cash flows.

Solara Shareholders Approve Mohanraj Sanjeevi as Whole-time Director with 99.97% Majority

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 10 Mar 2026, 01:02 PM

Solara Active Pharma Sciences Limited has announced the successful passage of a special resolution to appoint Mr. Mohanraj Sanjeevi as a Whole-time Director for a three-year term. The resolution received overwhelming support, with 99.97% of the 26.04 million votes cast in favor. Mr. Sanjeevi's remuneration is set at a fixed Rs. 85 lakh per annum plus a variable component of Rs. 15 lakh. This appointment, effective from January 1, 2026, ensures leadership stability for the company's executive operations.

Special resolution for appointment passed with 99.97% majority (26,032,102 votes in favor).
Mr. Mohanraj Sanjeevi appointed for a 3-year term effective from January 1, 2026, to December 31, 2028.
Total annual remuneration package includes Rs. 85 lakh fixed and Rs. 15 lakh variable pay.
Promoter and institutional investor groups both voted 100% in favor of the resolution.
Overall voter turnout represented 58.64% of the total outstanding shares of the company.

💡 The high level of shareholder support indicates strong confidence in the executive leadership. Investors should view this as a routine governance step providing management continuity.

Solara Active Pharma Closes Non-Operational Brazil Subsidiary; Nil Financial Impact

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Mar 2026, 05:01 PM

Solara Active Pharma Sciences has announced the voluntary deregistration of its wholly owned subsidiary in Brazil, Solara Active Pharma Sciences LTDA. The subsidiary was non-operational and contributed zero revenue and zero net worth to the company's consolidated financials for the fiscal year ended March 31, 2025. This move is part of a routine administrative cleanup of non-material entities. The closure was finalized with the Federal Revenue of Brazil and is effective from July 30, 2025.

Voluntary deregistration of wholly owned subsidiary Solara Active Pharma Sciences LTDA, Brazil.
The subsidiary contributed Nil turnover and Nil net worth to consolidated financials in FY25.
Closure is effective from July 30, 2025, following a period of no business activity.
The entity was classified as a non-material subsidiary with no impact on core operations.

💡 This is a routine administrative update regarding the dissolution of a shell entity. No action is required as there is no impact on the company's financial performance or strategic direction.

Solara Q3 FY26: Growth API Margins at 25% Amid Strategic Review of Ibuprofen Business

🔵 WATCH ⭐ 7/10

EARNINGS 📅 10 Feb 2026, 05:52 PM

Solara reported Q3 FY26 revenue of INR 346 crores, up 10% Q-o-Q, though consolidated gross margins fell to 47% due to headwinds in the base ibuprofen business. The non-ibuprofen 'growth' segment is performing exceptionally well with 56% gross margins and 25% EBITDA margins, significantly outperforming the commodity business. Management has initiated a strategic review of the ibuprofen division, which is currently utilizing only 3,000 tons of its 6,000-ton Pondicherry capacity. The company successfully reduced debt by INR 146 crores (19%) and targets a sub-INR 500 crore debt level by May 2026.

Revenue grew 10% Q-o-Q to INR 346 crores; EBITDA stood at INR 37 crores with an 11% margin.
Non-ibuprofen growth business achieved high-tier margins of 56% (gross) and 25% (EBITDA).
Ibuprofen capacity utilization remains low at 50% for the Pondicherry plant (3,000 of 6,000 tons).
Debt was reduced by INR 146 crores (19%) during the quarter, aided by rights issue proceeds.
A one-time exceptional cost of INR 6.7 crores was incurred due to the new labor wage code implementation.

💡 Investors should closely monitor the Q4 announcement regarding the strategic review of the ibuprofen business, as a potential restructuring or hive-off could unlock significant value from the high-margin growth API segment.

Solara Active Pharma Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 06 Feb 2026, 06:51 PM

Solara Active Pharma Sciences has officially released the audio recording of its Q3 FY26 earnings conference call held on February 06, 2026. The call provided management commentary on the company's financial performance for the quarter and nine-month period ending December 31, 2025. This disclosure is a routine regulatory requirement under SEBI LODR regulations to ensure transparency for all shareholders. Investors can access the full recording on the company's website to understand the business outlook and operational updates.

Audio recording of the Q3 FY26 earnings call made available on February 06, 2026.
Covers financial and operational performance for the nine months ended December 31, 2025.
Compliant with SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations 30 and 46.
Direct link to the audio file provided for immediate investor access via the corporate website.

💡 Investors should listen to the recording to evaluate management's guidance on API market recovery and debt reduction plans. This is a routine update and does not require immediate trading action unless specific material surprises were noted during the call.

Solara Reports Zero Deviation in ₹308.85 Cr Rights Issue Fund Utilization

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 06 Feb 2026, 02:38 PM

Solara Active Pharma Sciences has confirmed that there is no deviation or variation in the utilization of ₹308.85 crores raised through its Rights Issue as of December 31, 2025. The company has primarily used the proceeds for debt reduction, with ₹233.61 crores allocated to the repayment or pre-payment of borrowings. Additionally, ₹74.97 crores have been utilized for general corporate purposes out of a total planned allocation of ₹112.24 crores. The Audit Committee and monitoring agency CRISIL have reviewed and approved these statements without any adverse comments.

Total funds raised through the Rights Issue amounted to ₹308.85 crores as of December 31, 2025.
A significant portion of ₹233.61 crores was utilized for the repayment or pre-payment of outstanding borrowings.
₹74.97 crores were deployed for General Corporate Purposes (GCP), adhering to the 25% cap of gross proceeds.
The company reported zero deviation from the objects mentioned in the Letter of Offer dated May 09, 2024.
A minor balance of ₹0.26 crores remains in the escrow account to be utilized in upcoming quarters.

💡 Investors should take confidence in the company's disciplined use of capital for debt reduction, which should improve the balance sheet. Monitor upcoming earnings reports to see the positive impact of reduced interest costs on the bottom line.

Solara Active Pharma Updates Materiality and Related Party Transaction Policies

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 06 Feb 2026, 02:19 PM

Solara Active Pharma Sciences has updated its internal governance policies following a Board meeting on February 06, 2026. The revisions specifically target the Policy for Determining Materiality of Events and the Policy for Governance of Related Party Transactions. These changes are designed to align the company's internal frameworks with recent amendments to SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations. While these are procedural updates, they reflect the company's commitment to regulatory compliance and transparency in reporting.

Board approved amendments to the Policy for Determining Materiality of Events under Regulation 30 of SEBI LODR
Revised Policy for Governance of Related Party Transactions adopted to comply with Regulation 23 of SEBI LODR
The updates were finalized during the Board meeting held on February 06, 2026
Both amended policies are now available for public viewing on the company's official website

💡 This is a routine regulatory update and requires no immediate action from investors. Monitor the company's website for specific details of the revised policies to assess governance standards.

Solara Q3 FY26 Revenue Up 15% to ₹3,490M; Board to Evaluate Ibuprofen Business Options

🔵 WATCH ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 02:09 PM

Solara reported a 15% YoY revenue growth to ₹3,490 million in Q3 FY26, driven by its high-margin Growth API segment which achieved a 24.7% EBITDA margin. However, the company posted a net loss of ₹174 million as the commodity Ibuprofen business remains a significant drag with negative EBITDA margins of -22.9%. To address this structural challenge, the Board is appointing strategic advisors to evaluate options for the Ibuprofen business and re-assess the previously announced CRAMS split. Debt reduction is on track, with gross debt falling to ₹6,300 million from ₹7,760 million in March 2025.

Revenue grew 15% YoY to ₹3,490 million, though EBITDA fell 37% YoY to ₹374 million due to Ibuprofen pricing pressures.
Growth API segment (Ex-Ibuprofen) delivered strong performance with 56.3% gross margins and ₹608 million EBITDA.
Ibuprofen base business reported an EBITDA loss of ₹234 million for the quarter, prompting a strategic review.
Gross debt reduced to ₹6,300 million as of December 2025, with a target to reach ₹4,999 million by May 2026.
Board is re-evaluating the CRAMS & Polymers business split scheme with a new roadmap expected next quarter.

💡 Investors should closely monitor the upcoming strategic roadmap for the Ibuprofen business, as a potential divestment or restructuring could unlock value by isolating the high-growth, high-margin API portfolio.

Solara Active Pharma Q3 Revenue Grows to ₹349 Cr; Net Loss Widens to ₹17.43 Cr

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 01:47 PM

Solara Active Pharma reported a 16% YoY revenue growth to ₹349 crore for Q3 FY26, but the company's financial health remains under significant pressure. The net loss widened to ₹17.43 crore, impacted by a ₹6.75 crore exceptional item related to new labor codes. Concerns persist regarding liquidity as net current liabilities exceed assets by ₹92.44 crore, with accumulated losses reaching ₹329.64 crore. The company is banking on a pending ₹134.99 crore rights issue call to stabilize its capital position.

Revenue from operations rose to ₹349.00 crore in Q3 FY26 from ₹300.31 crore in Q3 FY25.
Net loss for the quarter stood at ₹17.43 crore versus a profit of ₹8.09 crore in the previous year's corresponding quarter.
Exceptional loss of ₹6.75 crore recorded due to gratuity and compensated absences impact under new labor codes.
Net current liabilities exceed net current assets by ₹92.44 crore as of December 31, 2025.
Company plans to raise ₹134.99 crore through the final call of its pending rights issue to fund operations.

💡 Investors should exercise caution given the widening losses and the 'going concern' notes regarding liquidity and working capital deficits. The stock's recovery depends heavily on the successful completion of the rights issue and a significant turnaround in operational margins.

Solara Pharma Issues Second Reminder for ₹131.25 First Call Money Payment

🟡 NEUTRAL ⭐ 6/10

FUNDRAISE 📅 04 Feb 2026, 11:06 PM

Solara Active Pharma Sciences has issued a second reminder notice for the payment of the First Call Money related to its Rights Issue. Shareholders holding partly paid-up shares are required to pay ₹131.25 per share, which includes ₹3.50 towards face value and ₹127.75 towards premium. The payment window is scheduled from February 5, 2026, to February 19, 2026. Upon successful payment, shares will be converted from a paid-up value of ₹3.50 to ₹7.00.

First Call Money amount is set at ₹131.25 per partly paid-up equity share
Payment period runs for 15 days from February 5, 2026, to February 19, 2026
Failure to pay will result in the forfeiture of shares and any amount already paid
Successful payment upgrades shares to ₹7.00 partly paid-up status under ISIN IN9624Z01022
Payments must be made electronically via the dedicated RTA portal using Net Banking or UPI

💡 Investors holding partly paid-up shares (ISIN: IN9624Z01014) must complete the payment by February 19, 2026, to prevent the forfeiture of their existing investment. Ensure the payment is made from the registered bank account to avoid rejection.

View All SOLARA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates as a pure-play API business. Total income was INR 1,294.29 Cr in FY24, a marginal decline of 0.2% YoY from INR 1,466.36 Cr in FY23. Q2 FY26 revenue was INR 314 Cr, representing a 10% YoY decline from INR 347.2 Cr in Q2 FY25 and a 2% QoQ decline from INR 320.1 Cr in Q1 FY26.

Geographic Revenue Split

Regulated markets remain the primary revenue driver, contributing 75% of overall sales in Q2 FY26, compared to 77% in Q1 FY26 and 76% in Q2 FY25. This concentration in regulated markets ensures higher quality standards but increases exposure to US FDA and EMA regulatory actions.

Profitability Margins

Gross margins remained resilient at 51% in Q2 FY26, though this was a 264 bps decline QoQ due to changes in the product mix. Net profitability saw a massive recovery from a PAT loss of INR 566.96 Cr in FY24 (PAT margin -43.97%) to a positive PAT of INR 0.54 Cr in FY25.

EBITDA Margin

EBITDA margin recovered to 16.5% (INR 213.84 Cr) in FY25 from a negative 7.1% (INR -92.03 Cr) in FY24. However, Q2 FY26 EBITDA margin dropped to 11.3% (INR 35.2 Cr), a 673 bps YoY decrease from 18.0% in Q2 FY25, driven by operational disruptions and one-time costs.

Capital Expenditure

The company has focused on debt reduction and equity infusion rather than large-scale new CapEx. Net debt to equity improved from 1.1x in FY24 to 0.7x in FY25. Specific investments include upgrading Effluent Treatment Plants (ETPs) and a INR 4 Cr facility upgradation at the Mangalore site.

Credit Rating & Borrowing

CRISIL maintains a Negative/Stable outlook. Interest coverage improved significantly to 2.12x in FY25 from -0.89x in FY24. Term debt obligations are approximately INR 100-117.25 Cr per annum, with bank limit utilization high at 95.68% as of late 2023.

⚙️ Operational Drivers

Raw Materials

Key raw materials include chemical intermediates for anthelmintic, anti-malaria, and NSAID APIs. While specific chemical names are not listed, raw material procurement and inventory levels are currently planned for sales exceeding INR 350 Cr per quarter.

Import Sources

Not specifically disclosed, though the company notes significant price competition from Chinese suppliers, implying China is a major sourcing or competitive benchmark region.

Capacity Expansion

The Vizag facility is currently 'mothballed' and will only resume operations once CRAMS (Contract Research and Manufacturing Services) partnerships are secured. The Mangalore facility recently underwent an unscheduled shutdown for facility upgradation.

Raw Material Costs

Raw material costs are a significant driver of the 49% cost of goods sold (implied by 51% gross margin). Deferred deliveries of high-margin products led to an inventory buildup of raw materials, increasing current liabilities.

Manufacturing Efficiency

Operational challenges in Q2 FY26 led to deferred deliveries of products worth INR 30-35 Cr. The company is focusing on network optimization and opex leverage to improve efficiency.

📈 Strategic Growth

Expected Growth Rate

12%

Growth Strategy

The company aims to pivot from a stable phase to a growth phase by targeting quarterly revenues of INR 350 Cr+. Key strategies include expanding the CRAMS business (Vizag plant), increasing focus on the non-steroidal anti-inflammatory (NSAID) segment, and reducing debt through equity infusions and rights issues.

Products & Services

Active Pharmaceutical Ingredients (APIs) for therapeutic segments including anthelmintic, anti-malaria, anti-infective, and non-steroidal anti-inflammatory drugs (NSAIDs) like Ibuprofen.

Brand Portfolio

Solara Active Pharma Sciences.

New Products/Services

The company is granting 3,50,000 stock options under the ESOP 2024 plan to align management with new product development and business expansion goals.

Market Expansion

Focusing on increasing market share in regulated markets (currently 75% of revenue) and diversifying the API portfolio into new therapeutic segments.

Market Share & Ranking

Positioned as a key player in the global API market, particularly in specialized segments like anthelmintics and NSAIDs.

Strategic Alliances

Actively seeking partnerships for the CRAMS division to utilize the currently mothballed Vizag facility.

🌍 External Factors

Industry Trends

The API industry is seeing a shift toward 'China+1' sourcing strategies, which Solara is positioned to benefit from, provided it maintains its 'stellar compliance record' and manages its 16.5% EBITDA margin targets.

Competitive Landscape

Faces intense competition from large-scale Chinese API manufacturers and other Indian pure-play API companies.

Competitive Moat

Moat is built on management's extensive experience, a robust compliance framework, and a 75% revenue contribution from high-entry-barrier regulated markets. Sustainability depends on avoiding further operational 'one-offs'.

Macro Economic Sensitivity

Highly sensitive to global pharmaceutical demand and healthcare regulatory shifts in the US and Europe.

Consumer Behavior

Demand is driven by global pharmaceutical companies' needs for high-quality, compliant API sources for generic and branded drugs.

Geopolitical Risks

Trade barriers or increased scrutiny on Indian API manufacturing sites by foreign regulators (US FDA) pose a constant risk to the export-heavy model.

⚖️ Regulatory & Governance

Industry Regulations

Strict adherence to global cGMP standards is mandatory. Most products face inspections from the US FDA; any adverse observations (Warning Letters) can halt sales to the US market.

Environmental Compliance

Requires continuous investment in Effluent Treatment Plants (ETPs) to manage waste discharge; non-compliance poses a risk to manufacturing licenses.

Legal Contingencies

The company states there are no significant or material orders passed by regulators or courts that impact its status as a going concern as of March 31, 2025.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the frequency of 'one-off' operational disruptions (fire, unscheduled shutdowns) which have historically caused EBITDA to swing from 16.5% to -7.1%.